Evidence map›Paper›PMID 39519254›Full record

ArticleInternational journal of molecular sciences2024

An Oxford Nanopore Technology-Based Hepatitis B Virus Sequencing Protocol Suitable for Genomic Surveillance Within Clinical Diagnostic Settings.

Derek Tshiabuila, Wonderful Choga, James E San, Tongai Maponga, Gert Van Zyl, Jennifer Giandhari, Sureshnee Pillay, Wolfgang Preiser, Yeshnee Naidoo, Cheryl Baxter and 2 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Derek TshiabuilaCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, Stellenbosch 7600, South Africa.
Wonderful ChogaCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, Stellenbosch 7600, South Africa.
James E SanDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-5736-664X
Tongai MapongaDivision of Medical Virology, National Health Laboratory Service Tygerberg, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 8000, South Africa.
Gert Van ZylDivision of Medical Virology, National Health Laboratory Service Tygerberg, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 8000, South Africa.ORCID 0000-0003-3021-5101
Jennifer GiandhariKwaZulu Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu Natal, Durban 4001, South Africa.ORCID 0000-0002-2944-4583
Sureshnee PillayKwaZulu Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu Natal, Durban 4001, South Africa.
Wolfgang PreiserDivision of Medical Virology, National Health Laboratory Service Tygerberg, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 8000, South Africa.ORCID 0000-0002-0254-7910
Yeshnee NaidooCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, Stellenbosch 7600, South Africa.
Cheryl BaxterCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, Stellenbosch 7600, South Africa.ORCID 0000-0002-6033-7655
Darren P MartinComputational Biology Division, Department of Integrative Biomedical Sciences, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town 8000, South Africa.
Tulio de OliveiraCentre for Epidemic Response and Innovation (CERI), Stellenbosch University, Stellenbosch 7600, South Africa.

Funding

University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
NIAID NIH HHS U01 AI151698
6 · The paper itself

Abstract

Chronic Hepatitis B Virus (HBV) infection remains a significant public health concern, particularly in Africa, where the burden is substantial. HBV is an enveloped virus, classified into ten phylogenetically distinct genotypes (A-J). Tests to determine HBV genotypes are based on full-genome sequencing or reverse hybridization. In practice, both approaches have limitations. Whereas diagnostic sequencing, generally using the Sanger approach, tends to focus only on the S-gene and yields little or no information on intra-patient HBV genetic diversity, reverse hybridization detects only known genotype-specific mutations. To resolve these limitations, we developed an Oxford Nanopore Technology (ONT)-based HBV diagnostic sequencing protocol suitable for clinical virology that yields both complete genome sequences and extensive intra-patient HBV diversity data. Specifically, the protocol involves tiling-based PCR amplification of HBV sequences, library preparation using the ONT Rapid Barcoding Kit (Oxford nanopore Technologies, Oxford, OX4 4DQ, UK), ONT GridION sequencing, genotyping using genome detective software v1.132/1.133, a recombination analysis using jpHMM (26 October 2011 version) and RDP5.61 software, and drug resistance profiling using Geno2pheno v2.0 software. We prove the utility of our protocol by efficiently generating and characterizing high-quality near full-length HBV genomes from 148 residual diagnostic samples from HBV-infected patients in the Western Cape province of South Africa, providing valuable insights into the genetic diversity and epidemiology of HBV in this region of the world.

Indexed as

Genome, ViralGenotypeHepatitis B virusDNA, ViralDrug Resistance, ViralGenetic VariationGenomicsHepatitis BHepatitis B, ChronicHigh-Throughput Nucleotide SequencingHumansNanoporesNanopore SequencingPhylogenySequence Analysis, DNADNA, ViralHBVNGSONTrecombinationwhole-genome sequencing

Identifiers

PMID39519254
PMCPMC11546910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.